Mankind Pharma Limited’s Board of Directors has approved the voluntary liquidation of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL). This decision aims to consolidate BSVL’s business operations with Mankind Pharma, driving operational efficiencies and improved resource utilization. BSVL’s business will be distributed to Mankind Pharma on a going concern basis, with minority shareholders receiving cash proportionate to their stake.
Mankind Pharma Approves BSVL Voluntary Liquidation
The Board of Directors of Mankind Pharma Limited has given its approval for the voluntary liquidation of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL). This strategic move is intended to prepare for the initiation of BSVL’s voluntary liquidation process and the subsequent integration of its business operations with the parent company.
Rationale and Expected Benefits
The primary objective behind this consolidation is to drive operational efficiency and ensure the effective utilization of resources currently managed by two separate legal entities. By integrating BSVL’s business, Mankind Pharma expects to achieve a consolidation of its material business segments. Furthermore, the company anticipates improved organizational execution capability and therapy leadership through the pooling of diverse human capital. Enhanced cash management, reduced compliance requirements, improved governance, and rationalized expenses are also expected benefits.
Business Distribution and Shareholding
Upon receipt of necessary approvals and documents, the business of BSVL will be distributed to Mankind Pharma on a going concern basis. The company holds 96% shares of BSVL, while Appian Properties Private Limited, a wholly-owned subsidiary of Mankind Pharma, holds the remaining 4% shares. Appian will receive cash proportionate to its shareholding, valued according to an independent valuer’s report. The proposed liquidation will be overseen by a liquidator appointed by BSVL, in compliance with applicable laws, including the Insolvency and Bankruptcy Code, 2016.
Impact on Shareholding Pattern
Pursuant to the voluntary liquidation, there will be no change in Mankind Pharma’s shareholding pattern. BSVL will be dissolved, and the shares held by Mankind Pharma and Appian will be cancelled.
Source: BSE
